Arca
Skip to content
Tools
Tools

Fatty liver

Drug research and approvals for fatty liver: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 22, 2026, 279 studies of fatty liver are recruiting on ClinicalTrials.gov, Health Canada has authorized 9 drug trials for it since 2013, FDA has 0 approved and 1 open orphan designations naming it, and the EU has 2 authorised medicines for it.

  • Recruiting worldwide: 279
  • Trials authorized in Canada: 9
  • FDA orphan approvals: 0
  • EU medicines: 2

Recruiting now

Newest posted first, of 279 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indications

Phase 3 7

Phase 2 7

Phase 1 or earlier 8

How its trials ended

1,576 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 318 whose ending is known, 48% met their primary endpoint, 9% missed it and 43% stopped early.

  • Completed, result not reported58337%
  • Ongoing42527%
  • Status unknown25016%
  • Met its primary endpoint15210%
  • Stopped: other or unclear664%
  • Stopped: enrollment or feasibility292%
  • Missed its primary endpoint282%
  • Stopped: sponsor or business decision191%
  • Stopped: lack of efficacy171%
  • Stopped: funding6<1%
  • Stopped: safety1<1%

Trials authorized in Canada

Newest first; search them all in Canada trials
Mar 28, 2025Stimulating adipose tissue fatty acid disposal with low-dose, postprandial, intermittent niacin for the treatment of metabolic dysfunction-associated steatotic…Nicotinic acid / Albumin / 11C palmitate / 18F fthaCiusss De L'Estrie - Centre Hospitalier Universitaire De SherbrookePending
Mar 7, 2025A phase 3, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of denifanstat in patients with metabolic dysfunction…Denifanstat (TVB-2640)Sagimet BiosciencesClosed
Sep 12, 2023A phase 3, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of efruxifermin in subjects with non-invasively diagnosed…Efruxifermin (EFX)Akero TherapeuticsOngoing
Jan 20, 2023A phase 1b study of QX1206 in type 2 diabetes mellitus (T2DM) patients with non-alcoholic fatty liver disease (NAFLD)Amcasertib (QX1206)1Globe Health InstituteOngoing
Jul 13, 2021A phase 2a, randomized, active-comparator-controlled, open-label study to evaluate the efficacy and safety of efinopegdutide (MK-6024) in individuals with…Efinopegdutide (MK-6024)/ SemaglutideMerck & Co. (MSD)Closed
Jun 18, 2021A randomized, double-blind, placebo-controlled, dose ranging study to evaluate the safety, tolerability, and efficacy of AXA1125 in subjects with…AXA1125Axcella HealthOngoing
Jul 10, 2019A phase 2, randomized, double-blind, placebo-controlled, multicenter, dose-finding study to evaluate the efficacy and safety of CC-90001 in subjects with…CC-90001Bristol-Myers SquibbClosed
Jul 4, 2019A phase 2a, randomized, double-blind, placebo-controlled, 3-arm, parallel group study to evaluation safety, tolerablity and pharmacodynamics of PF-06835919…PF-06835919PfizerClosed
Aug 29, 2017An adaptive design study for the assessment of the safety, tolerability, and pharmacokinetics of RYI-018 after repeat dosing in subjects with non-alcoholic…RYI-018Bird Rock Bio, IncPending

FDA orphan designations

Approved first, then open designations, newest first
DateDrugSponsorStatus
Mar 28, 2018FluasteroneTreatment of Cushing syndrome (including hyperglycemia, nonalcoholic fatty liver disease, and nonalcoholic steatosis)Sterotherapeutics, LLCDesignated

Medicines authorised in the EU

Newest first
Mar 26, 2026KayshildSemaglutideNovo Nordisk A/SEMA ↗
Aug 18, 2025RezdiffraResmetiromMadrigal Pharmaceuticals EU LimitedEMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.